Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 3/20 | 0.59 |
| ▸ | DHFR | P00374 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ACP1 | P24666 | 1/20 | 0.47 |
| ▸ | PGK1 | P00558 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019255 | 0.89 | TYMS (0.61) | TYMSDHFRTHRBMAPTTP53 | |
| SCHEMBL4019248 | 0.88 | TYMS (0.57) | TYMSDHFRMAPTTP53PIK3CA | |
| SCHEMBL4020733 | 0.87 | TYMS (0.59) | TYMSDHFRMAPTTP53PIK3CA | |
| SCHEMBL4026477 | 0.83 | TYMS (0.55) | TYMSDHFRMAPTTP53PIK3CA | |
| SCHEMBL27901724 | 0.82 | PIK3CA (0.58) | TYMSDHFRMAPTTP53PIK3CA | |
| SCHEMBL4026540 | 0.82 | PIK3CA (0.52) | TYMSDHFRTHRBMAPTTP53 | |
| SCHEMBL4019259 | 0.81 | MAPT (0.54) | MAPTTP53PIK3CDLMNAKDM4E | |
| SCHEMBL4016340 | 0.81 | ABCG2 (0.65) | TYMSDHFRMAPTPIK3CASMN1; SMN2 | |
| SCHEMBL10198786 | 0.79 | MAPT (0.58) | MAPTTP53PIK3CAPIK3CDPIK3CB | |
| SCHEMBL4018542 | 0.78 | ABCG2 (0.55) | TYMSDHFRMAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-22 | — | — | US | disclosed |
| US-8071597-B2 | Pyrazine compounds and uses as PI3K inhibitors | MERCK SERONO SA (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | TYMS 1605/4885DHFR 4026/4885THRB 2553/4885 |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | TYMS 822/4885DHFR 3763/4885THRB 1425/4885 |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | TYMS 822/4885DHFR 3763/4885THRB 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.